LON:ETXe-Therapeutics Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding e-Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 13.60 -0.03 (-0.22 %) (As of 08/11/2020 08:24 AM ET) Add Compare Share Today's Range 13.50Now: GBX 13.60▼ 13.7550-Day Range 11.13MA: GBX 13.92▼ 17.3852-Week Range 0.17Now: GBX 13.60▼ 23Volume480,688 shsAverage Volume54,267 shsMarket Capitalization£56.99 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsEarningsInsider TradesHeadlines e-Therapeutics plc engages in the discovery of drugs through its proprietary network-driven drug discovery platform in the United Kingdom. It is developing two NDD-derived immuno-oncology programs, including tryptophan catabolism and immune checkpoint modulation. The company, through its subsidiary, Searchbolt Limited, develops search engine technology. The company has collaborations with C4X Holdings PLC, Intellegens, Biorelate, and Novo Nordisk. e-Therapeutics plc was founded in 2001 and is based in Long Hanborough, the United Kingdom.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for e-Therapeutics. Previous Next 2.1 Community Rank Outperform Votese-Therapeutics has received 128 “outperform” votes. (Add your “outperform” vote.)Underperform Votese-Therapeutics has received 171 “underperform” votes. (Add your “underperform” vote.)Community Sentimente-Therapeutics has received 57.19% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about e-Therapeutics and other stocks. Vote “Outperform” if you believe ETX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ETX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend Yielde-Therapeutics does not currently pay a dividend.Dividend Growthe-Therapeutics does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, e-Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought £5,471.45 in company stock and sold GBX 0 in company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of e-Therapeutics is -15.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of e-Therapeutics is -15.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratioe-Therapeutics has a P/B Ratio of 8.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.02 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:ETX Previous Symbol CUSIPN/A CIKN/A Webwww.etherapeutics.co.uk Phone+44-1993-880000Debt Debt-to-Equity Ratio1.53 Current Ratio17.56 Quick Ratio16.99Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales£456,000.00 Price / Sales124.98 Cash FlowGBX 1.33 per share Price / Cash Flow10.25 Book ValueGBX 1.70 per share Price / Book8.00Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees18 Outstanding Shares419,056,992Market Cap£56.99 million Next Earnings DateN/A OptionableNot Optionable GBX 13.60 -0.03 (-0.22 %) (As of 08/11/2020 08:24 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ETX News and Ratings via Email Sign-up to receive the latest news and ratings for ETX and its competitors with MarketBeat's FREE daily newsletter. e-Therapeutics (LON:ETX) Frequently Asked Questions How has e-Therapeutics' stock been impacted by COVID-19? e-Therapeutics' stock was trading at GBX 8.10 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ETX stock has increased by 67.9% and is now trading at GBX 13.60. View which stocks have been most impacted by COVID-19. How were e-Therapeutics' earnings last quarter? e-Therapeutics plc (LON:ETX) issued its quarterly earnings results on Tuesday, March, 17th. The company reported ($0.87) EPS for the quarter, topping analysts' consensus estimates of ($0.90) by $0.03. View e-Therapeutics' earnings history. Has e-Therapeutics been receiving favorable news coverage? News stories about ETX stock have been trending neutral on Tuesday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. e-Therapeutics earned a daily sentiment score of 0.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about e-Therapeutics. Who are some of e-Therapeutics' key competitors? Some companies that are related to e-Therapeutics include BELLUS Health (BLU), Novacyt (NCYT), Bioventix (BVXP), Exicure (XCUR), Exicure (XCUR), Burcon NutraScience (BU), Faron Pharmaceuticals Oy (FARN), Enochian Biosciences (ENOB), Equillium (EQ), Ampio Pharmaceuticals (AMPE), Ampio Pharmaceuticals (AMPE), Neuren Pharmaceuticals (NEU), BiomX (PHGE), Matinas Biopharma (MTNB) and Matinas BioPharma (MTNB). View all competitors. What other stocks do shareholders of e-Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other e-Therapeutics investors own include Radware (RDWR), Sound Energy (SOU), 4d Pharma (DDDD), Chicken Soup for The Soul Entrtnmnt (CSSE), Crescent Point Energy (CPG), Collagen Solutions (COS), Bazaarvoice (BV), BP (BP), Bushveld Minerals (BMN) and ALSTOM/ADR (ALSMY). Who are e-Therapeutics' key executives? e-Therapeutics' management team includes the following people: Dr. Raymond Barlow, CEO & Director (Age 50)Mr. Steven Medlicott, CFO, Fin. Director & Exec. Director (Age 54)Mr. Jonny Wray, Head of Discovery InformaticsMr. Colin Stubberfield, Head of Drug DiscoveryMr. Alan Whitmore, Head of Discovery Biology What is e-Therapeutics' stock symbol? e-Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "ETX." How do I buy shares of e-Therapeutics? Shares of ETX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is e-Therapeutics' stock price today? One share of ETX stock can currently be purchased for approximately GBX 13.60. How big of a company is e-Therapeutics? e-Therapeutics has a market capitalization of £56.99 million and generates £456,000.00 in revenue each year. e-Therapeutics employs 18 workers across the globe. What is e-Therapeutics' official website? The official website for e-Therapeutics is www.etherapeutics.co.uk. How can I contact e-Therapeutics? e-Therapeutics' mailing address is 17 Blenheim Office Park, WITNEY, OX29 8LN, United Kingdom. The company can be reached via phone at +44-1993-880000. This page was last updated on 8/11/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
